Publications

Oncogene

A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.

28-07-2026

European journal of nuclear medicine and molecular imaging

Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry.

10-07-2026

Cancer discovery

Germline CDK12 variants in aggressive prostate cancer.

02-07-2026

European urology oncology

Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.

01-04-2026

European urology oncology

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.

01-04-2026

Annals of oncology : official journal of the European Society for Medical Oncology

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.

01-03-2026

NAR genomics and bioinformatics

DEprot: a comprehensive R-package for the analysis of label-free quantitation mass spectrometry data.

01-03-2026

Therapeutic drug monitoring

Impact of Abiraterone Therapeutic Drug Monitoring on Cortisol as a Surrogate Biomarker of CYP17 Inhibition in Metastatic Prostate Cancer Treatment.

13-02-2026

European urology oncology

Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.

01-08-2025

Cell reports. Medicine

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

15-07-2025

Communications biology

TRIM33 loss reduces androgen receptor transcriptional output and H2BK120 ubiquitination.

11-07-2025

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with ²²³Ra Therapy in Daily Practice.

01-07-2025

Clinical genitourinary cancer

Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

01-06-2025

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

10-05-2025

British journal of cancer

Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.

01-04-2025

Genome medicine

Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications.

20-03-2025

Cancer discovery

Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.

03-03-2025

The Journal of clinical investigation

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

19-11-2024

European urology oncology

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.

01-10-2024

The Journal of clinical investigation

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.

13-08-2024

Clinical genitourinary cancer

Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.

01-04-2024

NPJ systems biology and applications

Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties.

21-02-2024

Journal of clinical pharmacology

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

01-02-2024

Cancers

It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.

10-01-2024

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.

31-12-2023

Pharmaceutical research

Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.

01-12-2023

European urology

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.

01-11-2023

Cancer research communications

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

01-08-2023

Cancers

Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.

06-06-2023

Cancers

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options.

29-05-2023

Prostate cancer and prostatic diseases

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.

01-03-2023

European urology open science

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.

01-03-2023

Urologic oncology

Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer.

01-02-2023

European urology open science

Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl).

01-02-2023

European urology oncology

Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review.

01-02-2023

Clinica chimica acta; international journal of clinical chemistry

Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.

15-01-2023

Nature communications

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

30-11-2022

Endocrinology

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.

11-10-2022

Clinical chemistry and laboratory medicine

Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.

27-09-2022

Advances in experimental medicine and biology

Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

16-09-2022

Cancer discovery

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

02-09-2022

Drugs - real world outcomes

Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.

01-06-2022

Cancer chemotherapy and pharmacology

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.

01-06-2022

Clinical epigenetics

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.

04-05-2022

Clinical genitourinary cancer

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.

01-04-2022

Clinical genitourinary cancer

Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.

01-02-2022

Prostate cancer and prostatic diseases

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.

01-02-2022

Cell reports

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.

14-12-2021

Journal of palliative medicine

High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry.

01-12-2021

Nature communications

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.

04-11-2021

A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.

Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry.

Germline CDK12 variants in aggressive prostate cancer.

Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.

DEprot: a comprehensive R-package for the analysis of label-free quantitation mass spectrometry data.

Impact of Abiraterone Therapeutic Drug Monitoring on Cortisol as a Surrogate Biomarker of CYP17 Inhibition in Metastatic Prostate Cancer Treatment.

Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

TRIM33 loss reduces androgen receptor transcriptional output and H2BK120 ubiquitination.

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice.

Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.

Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications.

Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.

Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.

Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties.

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.

A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.

Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options.

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.

Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer.

Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl).

Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review.

Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.

Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.

Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.

Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.

High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry.

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.

This site uses cookies

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with ²²³Ra Therapy in Daily Practice.